Last reviewed · How we verify
TIVA - Neostigmine 70
TIVA - Neostigmine 70 is a Acetylcholinesterase inhibitor Small molecule drug developed by Pontificia Universidade Catolica de Sao Paulo. It is currently FDA-approved for Reversal of neuromuscular blockade, Myasthenia gravis, Postoperative ileus and urinary retention. Also known as: TIVA.
Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction and in the central nervous system.
Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine levels at the neuromuscular junction and in the central nervous system. Used for Reversal of neuromuscular blockade, Myasthenia gravis, Postoperative ileus and urinary retention.
At a glance
| Generic name | TIVA - Neostigmine 70 |
|---|---|
| Also known as | TIVA |
| Sponsor | Pontificia Universidade Catolica de Sao Paulo |
| Drug class | Acetylcholinesterase inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
By inhibiting the enzyme acetylcholinesterase, neostigmine prevents the breakdown of acetylcholine, leading to increased acetylcholine concentration in synaptic spaces. This enhances cholinergic neurotransmission at the neuromuscular junction and autonomic nervous system sites. The drug is used to reverse neuromuscular blockade and treat myasthenia gravis by prolonging the action of available acetylcholine.
Approved indications
- Reversal of neuromuscular blockade
- Myasthenia gravis
- Postoperative ileus and urinary retention
Common side effects
- Increased salivation
- Bronchospasm
- Bradycardia
- Muscle fasciculations
- Nausea and vomiting
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TIVA - Neostigmine 70 CI brief — competitive landscape report
- TIVA - Neostigmine 70 updates RSS · CI watch RSS
- Pontificia Universidade Catolica de Sao Paulo portfolio CI
Frequently asked questions about TIVA - Neostigmine 70
What is TIVA - Neostigmine 70?
How does TIVA - Neostigmine 70 work?
What is TIVA - Neostigmine 70 used for?
Who makes TIVA - Neostigmine 70?
Is TIVA - Neostigmine 70 also known as anything else?
What drug class is TIVA - Neostigmine 70 in?
What development phase is TIVA - Neostigmine 70 in?
What are the side effects of TIVA - Neostigmine 70?
What does TIVA - Neostigmine 70 target?
Related
- Drug class: All Acetylcholinesterase inhibitor drugs
- Target: All drugs targeting Acetylcholinesterase
- Manufacturer: Pontificia Universidade Catolica de Sao Paulo — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Reversal of neuromuscular blockade
- Indication: Drugs for Myasthenia gravis
- Indication: Drugs for Postoperative ileus and urinary retention
- Also known as: TIVA